NextCure, Inc. (NXTC)
6.18
-0.21
(-3.29%)
USD |
NASDAQ |
Sep 01, 10:10
NextCure Shareholders Equity (Quarterly) : 12.15M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 12.15M |
| March 31, 2026 | 26.72M |
| December 31, 2025 | 34.94M |
| September 30, 2025 | 23.65M |
| June 30, 2025 | 31.65M |
| March 31, 2025 | 55.86M |
| December 31, 2024 | 65.47M |
| September 30, 2024 | 75.59M |
| June 30, 2024 | 85.44M |
| March 31, 2024 | 99.05M |
| December 31, 2023 | 114.42M |
| September 30, 2023 | 126.45M |
| June 30, 2023 | 138.43M |
| March 31, 2023 | 154.20M |
| December 31, 2022 | 167.53M |
| Date | Value |
|---|---|
| September 30, 2022 | 181.54M |
| June 30, 2022 | 198.20M |
| March 31, 2022 | 213.94M |
| December 31, 2021 | 233.39M |
| September 30, 2021 | 248.23M |
| June 30, 2021 | 263.60M |
| March 31, 2021 | 279.16M |
| December 31, 2020 | 293.72M |
| September 30, 2020 | 307.34M |
| June 30, 2020 | 321.92M |
| March 31, 2020 | 331.76M |
| December 31, 2019 | 321.48M |
| September 30, 2019 | 170.65M |
| June 30, 2019 | 178.60M |
| March 31, 2019 | 109.51M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 22.62M |
| Total Liabilities (Quarterly) | 10.47M |
| Debt to Equity Ratio | 0.3529 |
| Current Ratio | 3.470 |
| Net Debt Paydown Yield | 4.78% |